TSXV:CVM.H - Post by User
Comment by
Nastroon Feb 28, 2019 10:21am
42 Views
Post# 29422586
RE:RE:RE:RE:RE:Re: Time Line
RE:RE:RE:RE:RE:Re: Time LineThe figure 31 relates to the number of de novo applications that were approved in 2017. The time to approval on average is 133 days from the date of submission.
slide 16 is a new slide as is 17, 25, 26, 27 & 28 so there is a fair bit of new material here. Slide 27 is interesting as it looks like they are evaluating 2 different revenue models, the first where they lease the device and charge a lower price for the consumables and the second where they give the device to the doctors for ‘free’ but charge double the price for the consumables. I guess they may decide to go down path 2 if they think it will lead to a faster adoption rate but yet to be determined.
the valuation comparison on page 28 is very interesting as I have looked at Helius in the past. It’s 7.5x greater market cap and also pre-revenue. I didn’t invest as I thought it very much a niche area rather than mass market like CVR.